- Raw materials
- Barbiturates
- Triclofos
Triclofos API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Triclofos | CAS No: 306-52-5 | GMP-certified suppliers
A medication that serves as a central nervous system depressant and hypnotic, primarily used to induce sedation and facilitate sleep in clinical settings.
Therapeutic categories
Product Snapshot
- Triclofos is an oral small molecule sedative agent
- It is primarily used for its hypnotic properties in sleep induction
- The compound has been approved and subsequently withdrawn in key regulatory markets including FDA jurisdictions
Clinical Overview
Clinically, Triclofos has been employed as a sedative-hypnotic agent, primarily used to induce sleep or sedation in various settings. Historical approvals for this compound exist; however, it has also been withdrawn from certain markets due to safety and regulatory considerations. Specific current global clinical indications are not consistently documented.
The precise pharmacodynamics and mechanism of action of Triclofos have not been definitively established in the literature. Like other hypnotic agents, it is believed to exert depressive effects on the central nervous system, likely through modulation of gamma-aminobutyric acid (GABA) receptor activity, although detailed receptor binding profiles and downstream effects remain inadequately characterized.
Key absorption, distribution, metabolism, and excretion (ADME) parameters are not comprehensively reported. It is generally noted that Triclofos undergoes hepatic metabolism and subsequent renal excretion. Due to the absence of robust pharmacokinetic data, careful consideration of patient-specific factors and potential interactions is warranted when used.
Safety and toxicity profiles indicate that, as with many centrally acting agents, Triclofos carries risks of respiratory depression, cognitive impairment, and potential for dependence or withdrawal phenomena upon prolonged use. Reports of adverse effects and varying regulatory decisions highlight the need for cautious clinical application.
Notable brand names and detailed usage contexts are limited or withdrawn in many jurisdictions, which underscores the importance of up-to-date regulatory consultation when considering this compound.
From an API sourcing perspective, procurement of Triclofos requires stringent quality control measures including verification of chemical identity (CAS Number 306-52-5), purity, and compliance with pharmacopeial standards. Given the compound’s complex regulatory status, suppliers must provide comprehensive documentation supporting regulatory compliance and batch-to-batch consistency to ensure suitability for formulation and clinical use.
Identification & chemistry
| Generic name | Triclofos |
|---|---|
| Molecule type | Small molecule |
| CAS | 306-52-5 |
| UNII | J712EO9048 |
| DrugBank ID | DB06753 |
Formulation & handling
- Triclofos is a small molecule intended for oral administration, given its solid state and moderate water solubility. Its monoalkyl phosphate structure suggests potential hydrolytic sensitivity, warranting protection from moisture during formulation and storage. Given its withdrawn status, ensure comprehensive evaluation of safety and regulatory compliance before procurement or development.
Regulatory status
Triclofos is a type of Barbiturates
Barbiturates are a category of pharmaceutical active pharmaceutical ingredients (APIs) that have sedative, hypnotic, and anticonvulsant properties. They belong to the class of drugs called depressants, which slow down the central nervous system (CNS) activity. Barbiturates have been widely used in the medical field for their ability to induce sleep, reduce anxiety, and control seizures.
The mechanism of action of barbiturates involves enhancing the effects of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain. GABA inhibits the transmission of signals between nerve cells, leading to relaxation and sedation. Barbiturates bind to specific GABA receptors, increasing the inhibitory effects of GABA and resulting in a calming effect on the CNS.
In the past, barbiturates were commonly prescribed for insomnia, anxiety disorders, and epilepsy. However, their use has decreased significantly due to the emergence of safer and more effective alternatives with fewer side effects. Nonetheless, barbiturates are still utilized in certain medical situations, such as anesthesia induction, emergency seizure control, and in some cases of refractory epilepsy.
Despite their therapeutic benefits, barbiturates carry potential risks and side effects. They can cause drowsiness, impaired coordination, and dependence when used for extended periods. Overdose of barbiturates can be life-threatening, leading to respiratory depression and coma.
In conclusion, barbiturates are a class of API widely known for their sedative, hypnotic, and anticonvulsant properties. While their use has diminished over time, they remain important in specific medical contexts. Proper caution and medical supervision are crucial when using barbiturates to ensure safety and efficacy.
